Raltitrexed is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase. Raltitrexed is a quinazoline folate analogue with antineoplastic activity. After transport into cells via the reduced folate carrier, raltitrexed undergoes intracellular polyglutamation and blocks the folate-binding site of thymidylate synthase, thereby inhibiting tetrahydrofolate activity and DNA replication and repair and resulting in cytotoxicity. It is grouped under the following drug class(es): Cytotoxics. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include raltitrexedum, Tomudex and ZD1694. Its PubChem CID is 135400182.
Raltitrexed
| CAS No | 112887-68-0 |
|---|---|
| Molecular Formula | C21H22N4O6S |
| Molecular Weight | 458.5 g/mol |
| Synonyms | (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Raltitrexed is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase. Raltitrexed is a quinazoline folate analogue with antineoplastic activity.
The listed CAS number is 112887-68-0.
The listed molecular formula is C21H22N4O6S.
The listed molecular weight is 458.5 g/mol.
(2S)-2-[[5-[methyl-[(2-methyl-4-oxo-3H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid.
The source lists raltitrexedum, Tomudex and ZD1694.